News Release
March 21, 2012
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. and Nordic Group BV have launched Anti-Cancer Drug TeysunoTM in Sweden, Denmark, Norway and Finland
Taiho Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Toru Usami) and Nordic Group BV (Head office: Hoofddorp, the Netherlands ; CEO and Managing Director: Drs. Hans Schram) have just started marketing of TeysunoTM , which has been developed by Taiho Pharmaceutical Co., Ltd., in Sweden, Denmark, Norway and Finland
Nordic Group BV has an exclusive right to commercialize TeysunoTM in the EU and other selected European Countries under the agreement with Taiho Pharmaceutical Co., Ltd.
TeysunoTM, a novel oral anti-cancer agent, received Marketing Authorization from the EMA for the treatment of adults with advanced gastric cancer when given in combination with cisplatin (March 14, 2011), which is on sale for the first time in this region.
About Nordic Group BV
The Nordic Group is a privately owned, fast growing, fully integrated, pan-European Pharmaceutical company, with a strong focus on the development and commercialization of niche hospital and orphan products and services that cater to the specific needs of clients and patients. In addition to its sales and marketing companies in 13 European countries, operating under the name of Nordic Pharma and Nordic Drugs, the Nordic Group operates as well a number of specialized Pharmaceutical Services companies, specialized in product development, manufacturing, supply logistics, clinical studies and regulatory activities. These companies are operating under the name of Prague Clinical Services, QPharma, Disphar and Indeus. Since its creation, Nordic has enjoyed an average growth of 20% in revenues, and it pursues its expansion through organic growth and strategic collaborations. Additional information can be obtained by visiting Nordic Groups website at www.nordicpharmagroup.com.
For further information please contact
Public Relations Dep.
Taiho Pharmaceutical Co., Ltd.
TEL:03-3293-2878 (Direct no.)
